{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:26:51Z","timestamp":1790310411575,"version":"4.1.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["tmreviews.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine Reviews"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.tmrv.2017.10.001","type":"journal-article","created":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T02:15:32Z","timestamp":1508120132000},"page":"69-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"title":["Purpura Fulminans: Mechanism and Management of Dysregulated Hemostasis"],"prefix":"10.1016","volume":"32","author":[{"given":"Meaghan E.","family":"Colling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavan K.","family":"Bendapudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tmrv.2017.10.001_bb0005","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1055\/s-2007-1002681","article-title":"Dermatopathology of skin necrosis associated with purpura fulminans","volume":"16","author":"Adcock","year":"1990","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0010","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1056\/NEJMra1316259","article-title":"Ischemic Limb Gangrene with Pulses","volume":"373","author":"Warkentin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0015","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1046\/j.1525-1470.1998.1998015169.x","article-title":"Acute infectious purpura fulminans: pathogenesis and medical management","volume":"15","author":"Darmstadt","year":"1998","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0020","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1136\/adc.2010.199919","article-title":"Purpura fulminans: recognition, diagnosis and management","volume":"96","author":"Chalmers","year":"2011","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0025","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/00000441-200612000-00006","article-title":"Purpura fulminans in sepsis","volume":"332","author":"Betrosian","year":"2006","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0030","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJM200108093450603","article-title":"Dysfunction of endothelial protein C activation in severe meningococcal sepsis","volume":"345","author":"Faust","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0035","doi-asserted-by":"crossref","first-page":"250","DOI":"10.7326\/0003-4819-67-2-250","article-title":"Intravascular coagulation in fulminant meningococcaemia","volume":"67","author":"McGehee","year":"1967","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0040","doi-asserted-by":"crossref","first-page":"R156","DOI":"10.1186\/cc9226","article-title":"Human protein C concentrate in the treatment of purpura fulminans: a retrospective analysis of safety and outcome in 94 pediatric patients","volume":"14","author":"Veldman","year":"2010","journal-title":"Crit Care"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0045","first-page":"43","article-title":"Purpura fulminans in meningococcal septicaemia in an adult: a case report","volume":"23","author":"Bollero","year":"2010","journal-title":"Ann Burns Fire Disasters"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0050","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199111283252207","article-title":"Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate","volume":"325","author":"Dreyfus","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0055","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0022-3476(95)70063-3","article-title":"Postinfectious purpura fulminans caused by an autoantibody directed against protein S","volume":"127","author":"Levin","year":"1995","journal-title":"J Pediatr"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0060","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0022-3476(96)70274-3","article-title":"Lupus anticoagulant and protein S deficiency in children with postvaricella purpura fulminans or thrombosis","volume":"128","author":"Manco-Johnson","year":"1996","journal-title":"J Pediatr"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0065","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1046\/j.1365-2141.1999.01186.x","article-title":"Infectious purpura fulminans: diagnosis and treatment","volume":"104","author":"Smith","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0070","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1203\/00006450-200109000-00009","article-title":"The varicella-autoantibody syndrome","volume":"50","author":"Josephson","year":"2001","journal-title":"Pediatr Res"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0075","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1055\/s-2007-1002684","article-title":"Acquired purpura fulminans","volume":"16","author":"Francis","year":"1990","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0080","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/00006454-199910000-00011","article-title":"Effect of the Factor V Leiden mutation on the severity of meningococcal disease","volume":"18","author":"Kondaveeti","year":"1999","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0085","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/S0140-6736(05)63910-4","article-title":"Genetic influence on cytokine production in meningococcal disease","volume":"349","author":"Westendorp","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0090","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12185-012-1059-0","article-title":"Protein C anticoagulant and cytoprotective pathways","volume":"95","author":"Griffin","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0095","first-page":"271","article-title":"Anticoagulant potential of endothelial cell membrane components","volume":"18","author":"Preissner","year":"1988","journal-title":"Haemostasis"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0100","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/01.ATV.12.2.135","article-title":"The protein C anticoagulant pathway","volume":"12","author":"Esmon","year":"1992","journal-title":"Arterioscler Thromb"},{"issue":"Suppl. 1","key":"10.1016\/j.tmrv.2017.10.001_bb0105","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/jth.12247","article-title":"Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway","volume":"11","author":"Bouwens","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0110","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1182\/blood-2014-09-599910","article-title":"Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar","volume":"125","author":"Aisiku","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0115","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1182\/blood-2009-09-201616","article-title":"The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications","volume":"115","author":"Danese","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0120","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.tins.2011.01.005","article-title":"Cytoprotective protein C pathways and implications for stroke and neurological disorders","volume":"34","author":"Zlokovic","year":"2011","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0125","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00281-011-0284-6","article-title":"Protein C anticoagulant system--anti-inflammatory effects","volume":"34","author":"Esmon","year":"2012","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0130","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1182\/blood-2004-01-0110","article-title":"Activated protein C variants with normal cytoprotective but reduced anticoagulant activity","volume":"104","author":"Mosnier","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0135","doi-asserted-by":"crossref","first-page":"33022","DOI":"10.1074\/jbc.M705824200","article-title":"Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions","volume":"282","author":"Mosnier","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0140","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood.V106.11.26.26","article-title":"Protective effect of activated protein C in murine endotoxemia: mechanism of action","volume":"106","author":"Kerschen","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0145","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1160\/TH03-03-0182","article-title":"Coagulopathy of sepsis","volume":"91","author":"Dempfle","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0150","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00281-011-0285-5","article-title":"Endothelium\u2014role in regulation of coagulation and inflammation","volume":"34","author":"van Hinsbergh","year":"2012","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0155","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1164\/rccm.201302-0228OC","article-title":"Assessment of the interplay between blood and skin vascular abnormalities in adult purpura fulminans","volume":"188","author":"Lerolle","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0160","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1084\/jem.140.1.159","article-title":"Role of meningococcal endotoxin in meningococcal purpura","volume":"140","author":"Davis","year":"1974","journal-title":"J Exp Med"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0165","first-page":"CR107","article-title":"Results of severe sepsis treatment program using recombinant human activated protein C in Poland","volume":"12","author":"Kubler","year":"2006","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0170","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00134-003-1784-1","article-title":"Combined antithrombin and protein C supplementation in meningococcal purpura fulminans: a pharmacokinetic study","volume":"29","author":"Fourrier","year":"2003","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0175","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1055\/s-0038-1651669","article-title":"Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality","volume":"73","author":"Fijnvandraat","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0180","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1053\/beha.2000.0067","article-title":"Disseminated intravascular coagulation and purpura fulminans secondary to infection","volume":"13","author":"Faust","year":"2000","journal-title":"Baillieres Best Pract Res Clin Haematol"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0185","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1055\/s-0038-1657503","article-title":"The protein C pathway: new insights","volume":"78","author":"Esmon","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0190","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1202290","article-title":"Drotrecogin alfa (activated) in adults with septic shock","volume":"366","author":"Ranieri","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0195","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1378\/chest.101.3.816","article-title":"Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies","volume":"101","author":"Fourrier","year":"1992","journal-title":"Chest"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0200","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1172\/JCI112902","article-title":"Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon","volume":"79","author":"Taylor","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0205","doi-asserted-by":"crossref","first-page":"27S","DOI":"10.1016\/0002-9343(89)80528-5","article-title":"Efficacy of antithrombin III supplementation in animal models of fulminant Escherichia coli endotoxemia or bacteremia","volume":"87","author":"Emerson","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0210","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM200103083441001","article-title":"Recombinant human protein. Efficacy and safety of recombinant human activated protein C for severe sepsis","volume":"344","author":"Bernard","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0215","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1164\/rccm.201211-2020OC","article-title":"Recombinant human activated protein C for adults with septic shock: a randomized controlled trial","volume":"187","author":"Annane","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0220","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1056\/NEJMoa050935","article-title":"G. Administration of drotrecogin alfa in early stage severe sepsis study. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death","volume":"353","author":"Abraham","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0225","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S0140-6736(07)60411-5","article-title":"Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial","volume":"369","author":"Nadel","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0230","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00134-009-1436-1","article-title":"Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock","volume":"35","author":"Dhainaut","year":"2009","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0235","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3109\/inf.1971.3.issue-2.06","article-title":"Fulminant meningococcemia. Heparin therapy and survival rate","volume":"3","author":"Manios","year":"1971","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0240","first-page":"43","article-title":"Heparin for infants and children with meningococcal septicemia. Results of a randomized therapeutic trial","volume":"6","author":"Haneberg","year":"1983","journal-title":"NIPH Ann"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0245","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0022-3476(73)80066-6","article-title":"Meningococcal purpura: report of 19 patients treated with heparin","volume":"82","author":"Gerard","year":"1973","journal-title":"J Pediatr"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0250","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/00006454-199410000-00004","article-title":"The role of heparin in the prevention of extremity and digit necrosis in meningococcal purpura fulminans","volume":"13","author":"Kuppermann","year":"1994","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0255","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM196706082762304","article-title":"Sequential coagulation studies in purpura fulminans","volume":"276","author":"Antley","year":"1967","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0260","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1097\/CCM.0b013e31818b8c6b","article-title":"Early intravenous unfractionated heparin and mortality in septic shock","volume":"36","author":"Zarychanski","year":"2008","journal-title":"Crit Care Med"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0265","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/CCM.0b013e31819c06bc","article-title":"Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study)","volume":"37","author":"Jaimes","year":"2009","journal-title":"Crit Care Med"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0270","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/CCM.0000000000000763","article-title":"The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis","volume":"43","author":"Zarychanski","year":"2015","journal-title":"Crit Care Med"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0275","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2141.2009.07600.x","article-title":"Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology","volume":"145","author":"Levi","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0280","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1161\/01.ATV.17.8.1568","article-title":"Induction of the acute-phase reaction increases heparin-binding proteins in plasma","volume":"17","author":"Young","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0285","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1097\/00003246-199609000-00002","article-title":"INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group","volume":"24","author":"Cohen","year":"1996","journal-title":"Crit Care Med"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0290","doi-asserted-by":"crossref","first-page":"771","DOI":"10.7326\/0003-4819-120-9-199405010-00009","article-title":"Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis","volume":"120","author":"Natanson","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0295","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/00003246-199605000-00003","article-title":"Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study","volume":"24","author":"Reinhart","year":"1996","journal-title":"Crit Care Med"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0300","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJM199606273342603","article-title":"Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group","volume":"334","author":"Fisher","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0305","first-page":"2693","article-title":"Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study","volume":"35","author":"Werdan","year":"2007","journal-title":"Crit Care Med"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0310","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/archsurg.133.1.94","article-title":"Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study","volume":"133","author":"Staubach","year":"1998","journal-title":"Arch Surg"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0315","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/00003246-199302000-00008","article-title":"Detrimental effects of high-dose methylprednisolone sodium succinate on serum concentrations of hepatic and renal function indicators in severe sepsis and septic shock. The Methylprednisolone Severe Sepsis Study Group","volume":"21","author":"Slotman","year":"1993","journal-title":"Crit Care Med"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0320","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1097\/00003246-199508000-00019","article-title":"Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature","volume":"23","author":"Cronin","year":"1995","journal-title":"Crit Care Med"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0325","first-page":"5","article-title":"Is There a Place for Apheresis in Patients with Severe Sepsis or Multi Organ Dysfunction Syndrome?","volume":"17","author":"Stegmayr","year":"2000","journal-title":"Turk J Haematol"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0330","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1046\/j.1525-1594.1998.06086.x","article-title":"Therapeutic apheresis for septic patients with organ dysfunction: hemoperfusion using a polymyxin B immobilized column","volume":"22","author":"Tani","year":"1998","journal-title":"Artif Organs"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0335","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1097\/00003246-199910000-00003","article-title":"Continuous plasmafiltration in sepsis syndrome. Plasmafiltration in Sepsis Study Group","volume":"27","author":"Reeves","year":"1999","journal-title":"Crit Care Med"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0340","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00006454-198906000-00015","article-title":"Plasmapheresis for fulminant meningococcemia","volume":"8","author":"Drapkin","year":"1989","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0345","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1046\/j.0007-1048.2002.03353.x","article-title":"Plasma exchange as a source of protein C for acute onset protein C pathway failure","volume":"116","author":"Hodgson","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0350","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1136\/bmj.288.6415.439","article-title":"Meningococcal septicaemia treated with combined plasmapheresis and leucapheresis or with blood exchange","volume":"288","author":"Bjorvatn","year":"1984","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0355","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/00130478-200007000-00016","article-title":"Antithrombin concentrate with plasma exchange in purpura fulminans","volume":"1","author":"Munteanu","year":"2000","journal-title":"Pediatr Crit Care Med"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0360","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1182\/blood-2015-02-355974","article-title":"Activated protein C: biased for translation","volume":"125","author":"Griffin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0365","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1097\/01.CCM.0000072121.61120.D8","article-title":"Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study","volume":"31","author":"de Kleijn","year":"2003","journal-title":"Crit Care Med"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0370","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1182\/blood.V96.12.3719","article-title":"An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia","volume":"96","author":"White","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0375","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1097\/00003246-200007000-00032","article-title":"Protein C substitution in sepsis-associated purpura fulminans","volume":"28","author":"Rintala","year":"2000","journal-title":"Crit Care Med"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0380","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1423-0410.2006.00760.x","article-title":"Treatment of adult patients with sepsis-induced coagulopathy and purpura fulminans using a plasma-derived protein C concentrate (Ceprotin)","volume":"90","author":"Schellongowski","year":"2006","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0385","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(97)06356-3","article-title":"Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans","volume":"350","author":"Smith","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0390","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1097\/00003246-199805000-00038","article-title":"Protein C in the treatment of coagulopathy in meningococcal disease","volume":"26","author":"Rintala","year":"1998","journal-title":"Crit Care Med"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0395","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0022-3476(95)70369-1","article-title":"Treatment of purpura fulminans in meningococcemia with protein C concentrate","volume":"126","author":"Rivard","year":"1995","journal-title":"J Pediatr"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0400","first-page":"691","article-title":"Replacement treatment with protein C in an 18-year-old man with meningococcal sepsis and purpura fulminans","volume":"69","author":"Vaccarella","year":"2003","journal-title":"Minerva Anestesiol"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0405","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00134-002-1605-y","article-title":"Drotrecogin alfa (activated) for the treatment of meningococcal purpura fulminans","volume":"29","author":"Bachli","year":"2003","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0410","first-page":"249","article-title":"Purpura fulminans during meningococcal sepsis treated with Drotrecogin alpha. A clinical case","volume":"72","author":"Belloni","year":"2006","journal-title":"Minerva Anestesiol"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0415","first-page":"535","article-title":"Treatment of acute infectious purpura fulminans with activated protein C","volume":"43","author":"Lokeshwar","year":"2006","journal-title":"Indian Pediatr"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0420","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1378\/chest.121.1.292","article-title":"Human recombinant activated protein C in meningococcal sepsis","volume":"121","author":"Wcisel","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0425","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/SMJ.0b013e318184b551","article-title":"Pneumococcal purpura fulminans successfully treated with activated protein C","volume":"101","author":"Minhas","year":"2008","journal-title":"South Med J"},{"key":"10.1016\/j.tmrv.2017.10.001_bb0430","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1542\/peds.91.2.418","article-title":"Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: treatment with protein C concentrate","volume":"91","author":"Gerson","year":"1993","journal-title":"Pediatrics"}],"container-title":["Transfusion Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796317300986?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796317300986?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T13:25:55Z","timestamp":1659619555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887796317300986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0887796317300986"],"URL":"https:\/\/doi.org\/10.1016\/j.tmrv.2017.10.001","relation":{},"ISSN":["0887-7963"],"issn-type":[{"value":"0887-7963","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Purpura Fulminans: Mechanism and Management of Dysregulated Hemostasis","name":"articletitle","label":"Article Title"},{"value":"Transfusion Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmrv.2017.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}